Education
About Us
Working with TipRanks
Follow Us
iSpecimen (ISPC)
NASDAQ:ISPC
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$0.23 - $3.18
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$2.44M
Enterprise Value-$1.11M
Total Cash (Recent Filing)$2.78M
Total Debt (Recent Filing)$281.44K
Price to Earnings (P/E)―
Beta0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,771,016
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.20
P/FCF Ratio-0.23
Enterprise Value/Market Cap-0.46
Enterprise Value/Revenue-0.33
Enterprise Value/Gross Profit-1.54
Enterprise Value/Ebitda0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform And NetworkiSpecimen’s technology-driven marketplace and broad provider partnerships create durable sourcing advantages for rare and diverse biospecimens. Network effects and institutional relationships support recurring demand from pharma and academia, improving long-term sample access and customer stickiness.
Low Financial LeverageVery low debt (debt-to-equity ~0.09) reduces solvency risk and preserves financial flexibility. This structural conservatism allows the company to pursue operational fixes or raise capital on less strained terms over the next several months, a durable mitigant to business stress.
Recent Capital RaiseThe $5.5M Series C private placement materially improves near-term liquidity and extends runway, enabling continued operations, sample sourcing, and investor outreach. As a structural financing event, it reduces immediate refinancing urgency over the next few months.
Bears Say
Sharp Revenue DeclineA ~43% TTM revenue drop signals weakening customer demand or loss of contracts, eroding scale and operating leverage. Sustained top-line decline undermines ability to cover fixed costs and invest in growth, increasing the risk that recovery will require structural changes or new commercial wins.
Margin CompressionGross margin roughly halved year-over-year, indicating either pricing pressure or higher procurement/fulfillment costs. This structural margin deterioration reduces cash generation per sale and means revenue recovery must be substantially larger to restore profitability and fund operations sustainably.
Persistent Cash BurnConsistent negative operating cash flow (~-$6.8M TTM) shows the core business consumes cash, forcing reliance on financing. Persistent burn increases dilution and restricts investment in product, compliance, or partnerships, making liquidity a central medium-term fundamental risk.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $0.23 and its highest was $3.18 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $2.44M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 9,771,016 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.43% Mutual Funds
<0.01% Other Institutional Investors
99.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---